NCT02431416View on ClinicalTrials.gov

Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

September 30, 2018

Conditions
Puberty, Precocious
Interventions
DRUG

Gonadotropin releasing hormone (GnRH)

Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.

DRUG

Sodium Chloride

Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.

Trial Locations (1)

701 85

Department of Paediatrics, Örebro University Hospital, Örebro

All Listed Sponsors
collaborator

Uppsala-Örebro Regional Research Council

OTHER

lead

Region Örebro County

OTHER

NCT02431416 - Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty | Biotech Hunter | Biotech Hunter